• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

SARS-CoV-2 vaccination for patients with inflammatory bowel disease - Authors' reply.

作者信息

Alexander James L, Kennedy Nicholas A, Lees Charlie W, Ahmad Tariq, Powell Nick

机构信息

Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK; Department of Gastroenterology, Imperial College Healthcare NHS Trust, London, UK.

Department of Gastroenterology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK; Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter, Exeter, UK.

出版信息

Lancet Gastroenterol Hepatol. 2021 Jul;6(7):523-524. doi: 10.1016/S2468-1253(21)00194-1.

DOI:10.1016/S2468-1253(21)00194-1
PMID:34119033
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8192089/
Abstract
摘要

相似文献

1
SARS-CoV-2 vaccination for patients with inflammatory bowel disease - Authors' reply.炎症性肠病患者的新型冠状病毒2型疫苗接种——作者回复
Lancet Gastroenterol Hepatol. 2021 Jul;6(7):523-524. doi: 10.1016/S2468-1253(21)00194-1.
2
SARS-CoV-2 vaccination for patients with inflammatory bowel disease.针对炎症性肠病患者的新型冠状病毒2型疫苗接种
Lancet Gastroenterol Hepatol. 2021 Jul;6(7):523. doi: 10.1016/S2468-1253(21)00148-5.
3
SARS-CoV-2 vaccination in immunosuppressed patients with inflammatory bowel disease: should our approach change?炎症性肠病免疫抑制患者的新型冠状病毒2型疫苗接种：我们的方法应该改变吗？
Lancet Gastroenterol Hepatol. 2021 Jul;6(7):528-529. doi: 10.1016/S2468-1253(21)00184-9. Epub 2021 May 26.
4
SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement.炎症性肠病患者的 SARS-CoV-2 疫苗接种：英国胃肠病学会炎症性肠病分会和 IBD 临床研究小组立场声明。
Lancet Gastroenterol Hepatol. 2021 Mar;6(3):218-224. doi: 10.1016/S2468-1253(21)00024-8. Epub 2021 Jan 26.
5
[SARS-CoV-2 Vaccination for Adult Patients with Inflammatory Bowel Disease: Expert Consensus Statements by KASID].[成人炎症性肠病患者的新型冠状病毒2型疫苗接种：韩国炎症性肠病学会专家共识声明]
Korean J Gastroenterol. 2021 Aug 25;78(2):117-128. doi: 10.4166/kjg.2021.110.
6
SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting.炎症性肠病患者的新型冠状病毒2型疫苗接种：一项国际共识会议的建议
Gut. 2021 Apr;70(4):635-640. doi: 10.1136/gutjnl-2020-324000. Epub 2021 Jan 20.
7
COVID-19 and Inflammatory Bowel Disease.新型冠状病毒肺炎与炎症性肠病。
Gastroenterol Clin North Am. 2023 Mar;52(1):103-113. doi: 10.1016/j.gtc.2022.10.005. Epub 2022 Oct 31.
8
Low Rates of Breakthrough COVID-19 Infection After SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease.炎症性肠病患者接种新型冠状病毒疫苗后新冠病毒突破性感染率较低
Inflamm Bowel Dis. 2023 Mar 1;29(3):483-486. doi: 10.1093/ibd/izac138.
9
Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination for Paediatric Patients With Inflammatory Bowel Diseases.严重急性呼吸综合征冠状病毒 2 疫苗接种用于炎症性肠病的儿科患者。
J Pediatr Gastroenterol Nutr. 2021 Oct 1;73(4):433-436. doi: 10.1097/MPG.0000000000003260.
10
Letter of Reply to "Response to: COVID-19 Vaccination Willingness and Hesitancy in Patients With Inflammatory Bowel Diseases: Analysis of Determinants in a National Survey of the Italian IBD Patients' Association".致《对〈炎症性肠病患者的新冠疫苗接种意愿与犹豫：意大利炎症性肠病患者协会全国调查中的决定因素分析〉的回应》的回复信
Inflamm Bowel Dis. 2022 Mar 30;28(4):e57-e58. doi: 10.1093/ibd/izab281.

引用本文的文献

1
SARS-CoV-2 vaccines: What we know, what we can do to improve them and what we could learn from other well-known viruses.严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）疫苗：我们所知道的、我们可以采取哪些措施来改进它们以及我们可以从其他知名病毒中学到什么。
AIMS Microbiol. 2022 Nov 16;8(4):422-453. doi: 10.3934/microbiol.2022029. eCollection 2022.
2
Safety of SARS-CoV-2 vaccination in patients with inflammatory bowel disease: A systematic review and meta-analysis.新型冠状病毒疫苗在炎症性肠病患者中的安全性：系统评价和荟萃分析。
Dig Liver Dis. 2022 Jun;54(6):713-721. doi: 10.1016/j.dld.2022.03.005. Epub 2022 Mar 22.

本文引用的文献

1
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD.英夫利昔单抗与 IBD 患者对 BNT162b2 和 ChAdOx1 nCoV-19 SARS-CoV-2 疫苗的免疫原性降低有关。
Gut. 2021 Oct;70(10):1884-1893. doi: 10.1136/gutjnl-2021-324789. Epub 2021 Apr 26.
2
SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement.炎症性肠病患者的 SARS-CoV-2 疫苗接种：英国胃肠病学会炎症性肠病分会和 IBD 临床研究小组立场声明。
Lancet Gastroenterol Hepatol. 2021 Mar;6(3):218-224. doi: 10.1016/S2468-1253(21)00024-8. Epub 2021 Jan 26.
3
Immunogenicity of the Currently Recommended Pneumococcal Vaccination Schedule in Patients With Inflammatory Bowel Disease.目前推荐的肺炎球菌疫苗接种方案在炎症性肠病患者中的免疫原性。
Clin Infect Dis. 2020 Feb 3;70(4):595-604. doi: 10.1093/cid/ciz226.
4
The effect of immunosuppressive agents on immunogenicity of pneumococcal vaccination: A systematic review and meta-analysis.免疫抑制剂对肺炎球菌疫苗免疫原性的影响：系统评价和荟萃分析。
Vaccine. 2018 Sep 18;36(39):5832-5845. doi: 10.1016/j.vaccine.2018.07.039. Epub 2018 Aug 16.